The Subsequent Infusions is a limited data collection project that is part of the retrospective de-identified data capture protocol, Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Kymriah⢠(Tisagenlecleucel) as an FDA-approved therapy.